Results 171 to 180 of about 53,382 (296)

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway   +24 more
wiley   +1 more source

Coexistence of Genetic Generalized Epilepsy and Temporal Lobe Epilepsy

open access: yesInternational Journal of Epilepsy, 2023
Kheta Ram Sharma   +3 more
openaire   +1 more source

Precision medicine in paediatrics: Progress and priorities

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain   +3 more
wiley   +1 more source

ACKR1/Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough   +29 more
wiley   +1 more source

Transforming Brain Health With Neurotechnology Convergence (Part II): Intelligent Neurointervention Systems for Neurological Disorders

open access: yesBrain Health, EarlyView.
ABSTRACT Neurological disorders represent a critical domain within global health, necessitating advanced interventions to address complex pathologies such as tumors, functional disorders, and cerebrovascular diseases. Despite the proven benefits of early intervention, current treatment paradigms face significant challenges: (1) limited precision in ...
Qing Ye   +14 more
wiley   +1 more source

Development and Retrospective Application of Novel Outcome Measure: Sturge–Weber Syndrome Acute Crisis (SWAC) Index

open access: yesAnnals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Sturge–Weber syndrome (SWS) symptoms frequently overlap in neurological acute crises (ACs) presenting with seizures, stroke‐like episodes (SLE), and headaches. Recent efforts to develop a prospective drug trial highlighted the need for a new outcome measure capable of quantifying these symptoms during an SWS AC.
Kieran D. McKenney   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy